Journals A-Z
All Subjects
Free Journals
sciepub.com
American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: https://www.sciepub.com/journal/ajmsm Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
Issue 4, Volume 9
Article Metrics
  • 22111
    Views
  • 23717
    Saves
  • 0
    Citations
  • 5
    Likes
Export Article
American Journal of Medical Sciences and Medicine. 2021, 9(4), 89-104
DOI: 10.12691/ajmsm-9-4-1
Open AccessReview Article

Updates in Transcatheter Aortic Valve Replacement

Omar Elsaka1, , Ashraf Hamada Abd Al-Razik1, Dalia Hisham1 and Abdulsalam Mahmoud Algamal1

1Department of Cardiology, Faculty of Medicine, Mansoura Manchester Medical Program (MMMP), Mansoura University, Mansoura, Egypt

Pub. Date: October 18, 2021
View Full Text Full Text PDF (1400 KB) Full Text ePUB(9981 KB)

Cite this paper:
Omar Elsaka, Ashraf Hamada Abd Al-Razik, Dalia Hisham and Abdulsalam Mahmoud Algamal. Updates in Transcatheter Aortic Valve Replacement. American Journal of Medical Sciences and Medicine. 2021; 9(4):89-104. doi: 10.12691/ajmsm-9-4-1

Abstract

Severe symptomatic aortic stenosis includes a poor diagnosis until recently; surgical aortic valve replacement has been the standard of care in adults with severe symptomatic aortic stenosis. Trans catheter aortic valve substitute (TAVR) become developed as an alternative to the surgical approach in this excessive-threat and inoperable populace. TAVR is a minimally invasive, catheter-primarily based method to replace the characteristic of the aortic valve. Indicated for patients at intermediate or greater risk for open heart surgery, TAVR may be an excellent option for certain patients because the prevalence of aortic stenosis and comorbidities may increase the risks associated with surgical aortic valve replacement (SAVR). The complete manner usually takes approximately 1-2 hours. At the beginning of the system, surgeons make a small incision in considered one of 3 locations, the groin, the neck, or an intercostal space. a skinny, flexible catheter with the coronary heart valve is guided via the incision into the artery and to the diseased valve. The TAVR heart valve is positioned inside the diseased or failing surgical valve; it begins working at once. The catheter is then removed and the incision closed.

Keywords:
TAVR SAVR updates transfemoral approach transcatheter valve implantation

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 26

References:

[1]  Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation. 2021(1). 119: 3009-16.
 
[2]  Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2019(2). 122: 62-9.
 
[3]  Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18F) CoreValve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention. 2017 (3). 4: 242-9.
 
[4]  Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2015 (4). 123:299-308.
 
[5]  Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve implantation: early results of the FRANCE (French Aortic National CoreValve and Edwards) registry. Eur Heart J. 2018 (5). 32: 191-7.
 
[6]  Zahn A, Gerckens U, Grube E, et al. Transcatheter aortic valve implantation: first results from a multicentre real-world registry. Eur Heart J. 2021(6). 32: 198-204.
 
[7]  Leon MB, Smith CR, Mack M, et al, for the PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2020(17) .21. 3631597-607.
 
[8]  Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2021(7). 364: 2187-98.
 
[9]  Holmes DR Jr, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2019 27. 59(13): 1200-54.
 
[10]  Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2017. 24(9): 882-3.
 
[11]  Edelman JJ, Thourani VH. Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies. J Thorac Cardiovasc Surg. 2018.; 156 (6):2135-2137.
 
[12]  Yu PJ, Mattia A, Cassiere HA, et al. Should high risk patients with concomitant severe aortic stenosis and mitral valve disease undergo double valve surgery in the TAVR era?. J Cardiothorac Surg. 2018 .29. 12 (1): 123.
 
[13]  Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2015 .18. 57(3): 253-69.
 
[14]  Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2017(6). 366: 1686-95.
 
[15]  Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2015(10). 366:1696-704.
 
[16]  Aldalati O, Kaura A, Khan H, et al. Bioprosthetic structural valve deterioration: how do TAVR and SAVR prostheses compare?. Int J Cardiol. (10) 2018. 1. 268: 170-5.
 
[17]  Danielsen SO, Moons P, Sandven I, et al. Thirty-day readmissions in surgical and transcatheter aortic valve replacement: A systematic review and meta-analysis. Int J Cardiol(20). 2018 .1. 268: 85-91.
 
[18]  Rodes-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol. (13) 2015. 57: 18-28.
 
[19]  Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation. (14) 2016. 121: 870-878.
 
[20]  Arnold M, Schulz-Heise S, Achenbach S, et al. Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging. J Am Coll Cardiol Intv (15). 2014. 3: 1126-1132.
 
[21]  Ghanem A, Muller A, Nahle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol. (16) 2015. 55: 1427-1432.
 
[22]  Berry C, Cartier R, Bonan R. Fatal ischemic stroke related to nonpermissive peripheral artery access for percutaneous aortic valve replacement. Catheter Cardiovasc Interv. (17) 2021. 69(1): 56-63.
 
[23]  Koos R, Mahnken AH, Aktug O, et al. Electrocardiographic and imaging predictors for permanent pacemaker requirement after transcatheter aortic valve implantation. J Heart Valve Dis.(18) 2014. 20: 83-90.
 
[24]  Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Timing and potential mechanisms of new conduction abnormalities during the implantation of the Medtronic CoreValve System in patients with aortic stenosis. Eur Heart J. (19)2021. 32: 2067-2074.
 
[25]  Oestreich BA, Mbai M, Gurevich S,et al. Computed tomography (CT) assessment of the membranous septal anatomy prior to transcatheter aortic valve replacement (TAVR) with the balloon-expandable SAPIEN 3 valve. Cardiovasc Revasc Med. 2020. 27(23).
 
[26]  Mangieri A, Lanzillo G, Bertoldi L, et al. Predictors of advanced conduction disturbances requiring a late (≥48 H) permanent pacemaker following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021 .13. 11 (15):1519-26.
 
[27]  Cribier A, Zajarias A, Eltchaninoff H, et al. Trans-catheter aortic valve interventions: from balloon aortic valvuloplasty to trans- catheter aortic valve implantation. Topol EJ, Teirstein PS, eds. Textbook of Interventional Cardiology. 6th ed. Philadelphia, PA: Elsevier; (40) 2017. 661-82.
 
[28]  Kahlert P, Al-Rashid F, Weber M, et al. Vascular access site complications after percutaneous transfemoral aortic valve implantation. Herz. 2018. 34(5): 398-408.
 
[29]  Hayashida K, Lefevre T, Chevalier B, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Interv. 2016. 4(8): 851-8.
 
[30]  Spaziano M, Lefèvre T, Romano M, Eltchaninoff H, Leprince P, Motreff P, Iung B, Van Belle E, Koning R, Verhoye JP, Gilard M, Garot P, Hovasse T, Le Breton H, Chevalier B. Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room: Insights From the FRANCE TAVI Registry. JACC Cardiovasc Interv. 2020. 12; 11(21): 2195-2203.
 
[31]  Makkar R. PARTNER 3 Low-Risk Computed Tomography (CT) Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves. Presented at TCT 2019, San Francisco, CA, (7) 2019.
 
[32]  Baim DS, ed. Grossman's Cardiac Catheterization, Angiography, and Intervention. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; (19) 2012.
 
[33]  Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015. 42 (2): 517-84.
 
[34]  Mihara H, Shibayama K, Jilaihawi H, et al. Assessment of post-procedural aortic regurgitation after TAVR: an intraprocedural TEE study. JACC Cardiovasc Imaging. 2019. 8(9): 993-1003.
 
[35]  Jensen HA, Condado JF, Devireddy C, et al. Minimalist transcatheter aortic valve replacement: The new standard for surgeons and cardiologists using transfemoral access. 2019.. 150(4): 833-40.
 
[36]  Liebetrau C, Gaede L, Kim WK, et al. Early changes in N-terminal pro-B-type natriuretic peptide levels after transcatheter aortic valve replacement and its impact on long-term mortality. Int J Cardiol. 2021. 15. 265: 40-6(23).
 
[37]  Schoen FJ. Cardiac valve prostheses: pathological and bioengineering considerations. J Card Surg. 2010. 2 (1): 65-108.
 
[38]  Sun W, Li K, Sirois E. Simulated elliptical bioprosthetic valve deformation: implications for asymmetric transcatheter valve deployment. J Biomech. 2015 1. 43 (16): 3085-90.
 
[39]  Borz B, Durand E, Tron C, et al. Expandable sheath for transfemoral transcatheter aortic valve replacement: procedural outcomes and complications. Catheter Cardiovasc Interv. 2019. 1. 83 (6): E227-32.
 
[40]  Popma JJ, Deeb GM, Yakubov SJ, et al, for the Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2020. 2. 380 (18): 1706-15.
 
[41]  Koehler T, Buege M, Schleiting H, Seyfarth M, Tiroch K, Vorpahl M. Changes of the esheath outer dimensions used for transfemoral transcatheter aortic valve replacement. Biomed Res Int. (33) 2018. 2015:572681.
 
[42]  Mack MJ, Leon MB, Thourani VH, et al, PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon- expandable valve in low-risk patients. N Engl J Med. 2020. 2. 380 (18): 1695-705.
 
[43]  Gunning PS, Saikrishnan N, Yoganathan AP, McNamara LM. Total ellipse of the heart valve: the impact of eccentric stent distortion on the regional dynamic deformation of pericardial tissue leaflets of a transcatheter aortic valve replacement. J R Soc Interface. 2019. 6. 12 (43): 20150737.
 
[44]  Chen S, Redfors B, Ben-Yehuda O, Crowley A, Greason KL, Alu MC, Finn MT, Vahl TP, Nazif T, Thourani VH, Suri RM, Svensson L, Webb JG, Kodali SK, Leon MB. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial. JACC Cardiovasc Interv. 2020 12; 11(39): 2207-2216.
 
Manuscript template